<DOC>
	<DOCNO>NCT01896336</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety sublingual zolpidem presentation 5 mg induction sleep patient primary insomnia .</brief_summary>
	<brief_title>Efficacy Safety 5 mg Sublingual Zolpidem vs 10mg Oral Zolpidem Induction Maintenance Sleep Patients With Primary Insomnia</brief_title>
	<detailed_description>- National study , phase IV , single-center , double-blind , randomize , parallel , control zolpidem 10mg oral . - Experiment duration : 93 day . - 05 visit ( day -3 , 0 , 15 , 45 90 ) . - Efficacy evaluate : Sleep induction maintenance sleep . - Adverse event evaluation .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Men woman age 20 64 year ; Diagnosis primary insomnia accord criterion define DSMIV ; Difficulty maintain sleep wake 3 ; Not use psychoactive drug last 30 day prior inclusion study ; Signature IC . Previous history serious medical illness , neurological psychiatric disorder ; Allergy hypersensitivity zolpidem ; Obstructive Sleep Apnea syndrome ; Polysomnography apnea hypopnea index &gt; 10/hour PLM &gt; 15/h ; Other secondary sleep disorder ; History substance abuse dependence ; History daily consumption alcoholic beverage ; Pregnancy , lactation refusal use safe contraceptive method study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>